Iceland· IS-EU/1/17/1226/001
Lutathera
A lutetium (177lu) oxodotreotide product containing lutetium (177lu) oxodotreotidum inn, registered in Iceland by Novartis Europharm Limited. The same ATC class is registered in 11 of our 19 countries.
Checked against Icelandic Medicines Agency (Iceland) on
Informational only — not a medical device.
Where it is registered
Lutetium (177lu) oxodotreotide is registered in 11 of 19 countries.
Countries holding a registration under ATC V10XX04 (lutetium (177lu) oxodotreotide), each read from that country’s own register.
- This record: Iceland, from Icelandic Medicines Agency (Iceland)
- 7 of them publish a price we can compare per daily dose
Lutetium (177lu) oxodotreotide · ATC V10XX04
11 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
The record
At a glance
Icelandic Medicines Agency (Iceland)- Active substance
- Lutetium (177Lu) oxodotreotidum INN
- Manufacturer
- Novartis Europharm Limited
- Country
- Iceland (IS)
- ATC code
- V10XX04
- ATC class
- Lutetium (177Lu) oxodotreotide
- Reimbursed
- Not published by this register
- Source register
- Icelandic Medicines Agency (Iceland)
- Last checked
- September 29, 2026
Packs & prices · 1
1 priced- ean1692581 hgl x1 pakkiISK 2966583
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same class
Other records under V10XX04
Lutetium (177lu) oxodotreotide, as other registers publish it.
- NetherlandsEndolucinBeta 40 GBq/mL, radiofarmaceutische precursor, oplossingITM Medical Isotopes GmbH
- PolandLumarkI.D.B. Holland B.V.
- FinlandLutatheraNovartis Europharm Limited
- NorwayLutatheraNovartis Europharm Limited
- PolandLutatheraAdvanced Accelerator Applications
- DenmarkLutatheraNovartis Europharm Limited
- CanadaLUTATHERANOVARTIS PHARMACEUTICALS CANADA INC
- CzechiaLUTATHERANovartis Europharm Limited, Dublin
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Icelandic Medicines Agency (Iceland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/88be26e4-4aea-4db1-ab97-3cfd51a408c8 GET /v1/drugs/88be26e4-4aea-4db1-ab97-3cfd51a408c8?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Innrennslislyf, lausn",
"source": "lyfjastofnun",
"atc_raw": "V10XX04",
"marketed": true,
"strength": "370 MBq/ml",
"ma_number": "EU/1/17/1226/001",
"substance": "Lutetium (177Lu) oxodotreotidum INN",
"other_info": "Markaðssetning á Íslandi er háð því að Lyfjastofnun hafi staðfest að sérstök skilyrði er varða öryggi og verkun við notkun lyfsins séu uppfyllt.",
"legal_status": "(R) Lyfseðilsskylt\r\n(H) Sjúkrahúsmerkt",
"ma_issued_serial": "43004"
}See everything about lutetium (177lu) oxodotreotide.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.